New insider activity at PTC Therapeutics ( (PTCT) ) has taken place on April 5, 2025.
EVP & Chief Medical Officer Lee Scott Golden has sold 897 shares of PTC Therapeutics stock, amounting to a total value of $42,114.
Recent Updates on PTCT stock
In the last 24 hours, PTC Therapeutics experienced significant developments affecting its stock. The European Commission adopted a negative opinion from the Committee for Medicinal Products for Human Use, deciding not to renew the conditional marketing authorization for Translarna in the European Economic Area. Despite this setback, individual EU member states may still allow its use, emphasizing the drug’s safety and benefits for patients with nonsense mutation Duchenne muscular dystrophy. Meanwhile, JPMorgan adjusted its price target for PTC Therapeutics, reflecting updates to the company’s model and the potential market impact of sepiapterin, a treatment for phenylketonuria (PKU). The positive feedback from U.S. physicians regarding sepiapterin’s treatment profile and expected uptake in the PKU treatment landscape contributed to this adjustment, with anticipated approval and launch in the second half of 2025.
More about PTC Therapeutics
YTD Price Performance: 1.85%
Average Trading Volume: 829,799
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.69B